Article

Bbarrons.com on 2020-09-10 16:29

FDA Delays Start of Sarepta’s Gene Therapy Trial

The delay will cost the company a few months at most, analysts say.

Wall Street

Related news

BBioMarin Slumps After FDA Rejects Its Hemophilia Gene Therapy barrons.com
Phase 1 , Wall Street
Shares of Solid Biosciences crater as FDA halts Duchenne gene therapy trial bizjournals.com
Seeing hope: FDA panel considers gene therapy for blindness The Wichita Eagle
Massachusetts , Europe , Long Island , Dallas , Philadelphia
FDA blocks much-anticipated BioMarin hemophilia gene therapy dailyherald.com
San Rafael
TFDA Document Raises Concerns Over a New Gene Editing Therapy theepochtimes.com
Dangers , California
FDA approves gene therapy for a type of blindness WXII
New York , Americas , United States
FDA OKs 1st gene therapy for use in U.S.wbrc.com
China , United States
DFDA approves CRISPR gene therapy trials for sickle cell disease dailycal.org
United States
FDA grants rare pediatric disease designation to RegenxBio gene therapy bizjournals.com
FDA approves first 'living drug' that uses gene therapy to fight cancer LA Times
Switzerland , Seattle , Morris Plains , Philipsburg , Philadelphia
MSarepta stock rises after FDA lifts clinical hold on gene therapy program marketwatch.com
FDA Finalizes Guidance On Interpretation Of Orphan Drug “Sameness” For Gene Therapy Products jdsupra.com
United States
BSarepta's Gene Therapy Set for Quick FDA Review 3 min read barrons.com